Aditya Shreenivas, MD, MS, discusses the FDA approval of penpulimab plus chemotherapy for the frontline treatment of non-keratinizing nasopharyngeal carcinoma.
Aditya V. Shreenivas, MD, MSCR
Advertisement
Aditya Shreenivas, M.D., M.S. is an assistant clinical professor in the Department of Medical Oncology & Therapeutics Research at City of Hope.
Articles by Aditya V. Shreenivas, MD, MSCR
Aditya Shreenivas, MD, MS, discusses the association between MUC1 and Claudin 18 in GI cancers.
Aditya V. Shreenivas, MD, MSCR, says a habit of continuous learning is the ideal way to stay informed about the latest data.
Advertisement
Latest Updated Articles
Keeping Ahead of Oncology Advances Requires VigilancePublished: September 11th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma
4
Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma
5